JPRN-jRCT2071220046已完成1 期
A RELATIVE AND ABSOLUTE BIOAVAILABILITY STUDY OF AMY109 WITH HEALTHY MALE VOLUNTEERS
Hashimoto Akiko0 个研究点目标入组 60 人开始时间: 2022年8月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 55age old（—）
- 性别
- Male
入选标准
- •Written informed consent must be obtained from the subject.
- •Body mass index (BMI) between 18.5 and < 30.0 kg/m2 at screening.
排除标准
- •Subject with cardiovascular disease, renal disease, hepatic disease, gastrointestinal disease, hematological disease, immunological disease, neurological disease, endocrine disease, metabolic disease, or pulmonary disease.
- •History of malignancy or leukemia within 10 years before screening.
研究者
相似试验
已完成
不适用
A Study to Evaluate the Relative Bioavailability and Effect of Food on Two Formulations of the MK-3682A Fixed-Dose Combination Tablets (MK-3682/MK-5172/MK-8742, 300 mg/ 100 mg/50 mg) in Healthy Adult Subjects.HCVHepatitis C virus10047438NL-OMON41736Merck Sharp & Dohme (MSD)22
已完成
不适用
A study to evaluate the relative bioavailability and effect of food on two 450mg MK-3682 Fixed-Dose Combination Formulations (MK-3682 /MK-5172 /MK-8408)10047438Hepatitis CNL-OMON41967Merck Sharp & Dohme (MSD)24
已完成
不适用
A study to evaluate the relative bioavailability and effect of food on MK-3682B Fixed-Dose Combination Tablet (MK-3682/MK-8408/MK-5172)10047438Hepatitis CNL-OMON41831QPS Netherlands B.V.22
已完成
1 期
A Phase 1 Study of Two PRN1008 Tablet Formulations and the impact of Midazolam and Famotidine on PRN1008 in Healthy SubjectsACTRN12618000249257Principia Biopharma Inc14
进行中（未招募）
1 期
Phase I Relative Bioavailability and food effect studyEUCTR2016-002895-29-DEBayer AG